A case of severe pityriasis rubra pilaris with a dramatic response to apremilast
- 1 January 2018
- journal article
- letter
- Published by John Libbey Eurotext in European Journal Of Dermatology
- Vol. 28 (1), 128-129
- https://doi.org/10.1684/ejd.2017.3187
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)Journal of the American Academy of Dermatology, 2017
- Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra PilarisJAMA Dermatology, 2016
- Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor ApremilastJAMA Dermatology, 2016
- Treatment Options for Pityriasis Rubra Pilaris Including Biologic AgentsJAMA Dermatology, 2014
- New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastDrug Design, Development and Therapy, 2013
- Pityriasis Rubra PilarisAmerican Journal of Clinical Dermatology, 2010